<?xml version="1.0" encoding="UTF-8"?>
<ref id="B308-pharmaceuticals-14-00381">
 <label>308.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Marin</surname>
    <given-names>R.-C.</given-names>
   </name>
   <name>
    <surname>Behl</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Negrut</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Bungau</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Management of Antiretroviral Therapy with Boosted Protease Inhibitorsâ€”Darunavir/Ritonavir or Darunavir/Cobicistat</article-title>
  <source>Biomedicines</source>
  <year>2021</year>
  <volume>9</volume>
  <elocation-id>313</elocation-id>
  <pub-id pub-id-type="doi">10.3390/biomedicines9030313</pub-id>
  <?supplied-pmid 33803812?>
  <pub-id pub-id-type="pmid">33803812</pub-id>
 </element-citation>
</ref>
